Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Infectious Diseases
Published in: BMC Infectious Diseases 1/2010

Open Access 01-12-2010 | Research article

The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials

Authors: Siddharth H Sheth, Robin J Larson

Published in: BMC Infectious Diseases | Issue 1/2010

Login to get access

Abstract

Background

HIV-associated lipodystrophy syndrome (HALS) is characterized by insulin resistance, abnormal lipid metabolism and redistribution of body fat. To date, there has been no quantitative summary of the effects of insulin sensitizing-agents for the treatment of this challenging problem.

Methods

We searched MEDLINE, the Cochrane Library, clinical trial registries, conference proceedings and references for randomized trials evaluating rosiglitazone, pioglitazone or metformin in patients with evidence of HALS (last update December 2009). Two reviewers independently abstracted data and assessed quality using a standard form. We contacted authors for missing data and calculated weighted mean differences (WMD) and 95% confidence intervals (CI) for each outcome.

Results

Sixteen trials involving 920 patients met inclusion criteria. Rosiglitazone modestly improved fasting insulin (WMD -3.67 mU/L; CI -7.03, -0.31) but worsened triglycerides (WMD 32.5 mg/dL; CI 1.93, 63.1), LDL (WMD 11.33 mg/dL; CI 1.85, 20.82) and HDL (WMD -2.91 mg/dL; CI -4.56, -1.26) when compared to placebo or no treatment in seven trials. Conversely, pioglitazone had no impact on fasting insulin, triglycerides or LDL but improved HDL (WMD 7.60 mg/dL; CI 0.20, 15.0) when compared to placebo in two trials. Neither drug favorably impacted measures of fat redistribution. Based on six trials with placebo or no treatment controls, metformin reduced fasting insulin (WMD -8.94 mU/L; CI -13.0, -4.90), triglycerides (WMD -42.87 mg/dL; CI -73.3, -12.5), body mass index (WMD -0.70 kg/m2; CI -1.09, -0.31) and waist-to-hip ratio (WMD -0.02; CI -0.03, 0.00). Three trials directly compared metformin to rosiglitazone. While effects on insulin were comparable, lipid levels and measures of fat redistribution all favored metformin. Severe adverse events were uncommon in all 16 trials.

Conclusion

Based on our meta-analysis, rosiglitazone should not be used in HALS. While pioglitazone may be safer, any benefits appear small. Metformin was the only insulin-sensitizer to demonstrate beneficial effects on all three components of HALS.
Appendix
Available only for authorised users
Literature
1.
Grinspoon SK: Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. American Journal of Medicine. 2005, 118 (Suppl 2): 23S-28S.PubMed
2.
Thiebaut R, Daucourt V, Mercie P, Ekouevi DK, Malvy D, Morlat P, Dupon M, Neau D, Farbos S, Marimoutou C, et al: Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clinical Infectious Diseases. 2000, 31 (6): 1482-1487. 10.1086/317477.CrossRefPubMed
3.
Burgoyne R, Collins E, Wagner C, Abbey S, Halman M, Nur M, Walmsley S: The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Quality of Life Research. 2005, 14 (4): 981-990. 10.1007/s11136-004-2580-2.CrossRefPubMed
4.
Duran S, Saves M, Spire B, Cailleton V, Sobel A, Carrieri P, Salmon D, Moatti JP, Leport C, Group AS: Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001, 15 (18): 2441-2444. 10.1097/00002030-200112070-00012.CrossRefPubMed
5.
Dolan SE, Hadigan C, Killilea KM, Sullivan MP, Hemphill L, Lees RS, Schoenfeld D, Grinspoon S: Increased cardiovascular disease risk indices in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 2005, 39 (1): 44-54. 10.1097/01.qai.0000159323.59250.83.CrossRefPubMed
6.
Hadigan C, Meigs JB, Wilson PWF, D'Agostino RB, Davis B, Basgoz N, Sax PE, Grinspoon S: Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clinical Infectious Diseases. 2003, 36 (7): 909-916. 10.1086/368185.CrossRefPubMed
7.
Bergersen BM: Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy. Drugs. 2006, 66 (15): 1971-1987. 10.2165/00003495-200666150-00006.CrossRefPubMed
8.
The Data Collection on Adverse Events of Anti HIVDSG: Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med. 2003, 349 (21): 1993-2003. 10.1056/NEJMoa030218.CrossRef
9.
Group DADS, Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AdA, El-Sadr W, Thiebaut R, De Wit S, Kirk O: Class of antiretroviral drugs and the risk of myocardial infarction.[see comment]. New England Journal of Medicine. 2007, 356 (17): 1723-1735. 10.1056/NEJMoa062744.CrossRef
10.
Grinspoon S, Carr A: Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. New England Journal of Medicine. 2005, 352 (1): 48-10.1056/NEJMra041811.CrossRefPubMed
11.
Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O: Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scandinavian Journal of Infectious Diseases. 2004, 36 (4): 244-253. 10.1080/00365540410019381.CrossRefPubMed
12.
Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, et al: Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.[see comment]. JAMA. 2002, 288 (2): 207-215. 10.1001/jama.288.2.207.CrossRefPubMed
13.
Moyle GJ, Sabin CA, Cartledge J, Johnson M, Wilkins E, Churchill D, Hay P, Fakoya A, Murphy M, Scullard G, et al: A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS. 2006, 20 (16): 2043-2050. 10.1097/01.aids.0000247574.33998.03.CrossRefPubMed
14.
Waters L, Nelson M: Long-term complications of antiretroviral therapy: lipoatrophy. International Journal of Clinical Practice. 2007, 61 (6): 999-1014. 10.1111/j.1742-1241.2007.01385.x.CrossRefPubMed
15.
Drechsler H, Powderly WG: Switching Effective Antiretroviral Therapy: A Review. Clinical Infectious Diseases. 2002, 35 (10): 1219-1230. 10.1086/343050.CrossRefPubMed
16.
Deeks ED, Keam SJ: Rosiglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2007, 67 (18): 2747-2779. 10.2165/00003495-200767180-00008.CrossRefPubMed
17.
Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. The American Journal of Medicine. 2001, 111 (1): 10-17. 10.1016/S0002-9343(01)00713-6.CrossRefPubMed
18.
Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S, Diabetes Prevention Program Research G: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.[see comment][summary for patients in Ann Intern Med. 2005 Apr 19;142(8):I46; PMID: 15838061]. Annals of Internal Medicine. 2005, 142 (8): 611-619.CrossRefPubMedPubMedCentral
19.
Bailey CJ, Turner RC: Metformin. N Engl J Med. 1996, 334 (9): 574-579. 10.1056/NEJM199602293340906.CrossRefPubMed
20.
Golay A: Metformin and body weight. International Journal of Obesity. 2008, 32 (1): 61-72. 10.1038/sj.ijo.0803695.CrossRefPubMed
21.
Diehl LA, Fabris BA, Barbosa DS, De Faria EC, Wiechmann SL, Carrilho AJF: Metformin increases HDL3-cholesterol and decreases subcutaneous truncal fat in nondiabetic patients with HIV-associated lipodystrophy. AIDS Patient Care & Stds. 2008, 22 (10): 779-786.CrossRef
22.
Kahn CR, Chen L, Cohen SE: Unraveling the mechanism of action of thiazolidinediones. Am Soc Clin Investig. 2000, 106: 1305-1307. 10.1172/JCI11705.CrossRef
23.
Hadigan C: Peroxisome proliferator-activated receptor gamma agonists and the treatment of HIV-associated lipoatrophy: unraveling the molecular mechanism of their shortcomings. Journal of Infectious Diseases. 2008, 198 (12): 1729-1731. 10.1086/593180.CrossRefPubMed
24.
Arioglu E, Duncan-Morin J, Sebring N: Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Annals of Internal Medicine. 2000, 133 (4): 263-274.CrossRefPubMed
25.
Benavides S, Nahata MC: Pharmacologic therapy for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2004, 38 (3): 448-457. 10.1345/aph.1D081.CrossRefPubMed
26.
McGoldrick C, Leen CLS: The management of dyslipidaemias in antiretroviral-treated HIV infection: a systematic review. HIV Medicine. 2007, 8 (6): 325-334. 10.1111/j.1468-1293.2007.00480.x.CrossRefPubMed
27.
Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.[Erratum appears in N Engl J Med. 2007 Jul 5;357(1):100.]. New England Journal of Medicine. 2007, 356 (24): 2457-2471. 10.1056/NEJMoa072761.CrossRefPubMed
28.
Robinson KA, Dickersin K: Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology. 2002, 31 (1): 150-153. 10.1093/ije/31.1.150.CrossRefPubMed
29.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials. 1996, 17 (1): 1-12. 10.1016/0197-2456(95)00134-4.CrossRefPubMed
30.
Despres J-P, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, Lupien P-J: Hyperinsulinemia as an Independent Risk Factor for Ischemic Heart Disease. N Engl J Med. 1996, 334 (15): 952-958. 10.1056/NEJM199604113341504.CrossRefPubMed
31.
Livingston EH, Chandalia M, Abate N: Do current body mass index criteria for obesity surgery reflect cardiovascular risk?. Surgery for Obesity & Related Diseases. 2007, 3 (6): 577-585.CrossRef
32.
Seidell JC, Perusse L, Despres JP, Bouchard C: Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. American Journal of Clinical Nutrition. 2001, 74 (3): 315-321.PubMed
33.
Higgins J, Green S: Cochrane Handbook for Systematic Reviews of Interventions, vol. 5.0.1. The Cochrane Collaboration. 2008
34.
van Wijk JPH, de Koning EJP, Cabezas MC, op't Roodt J, Joven J, Rabelink TJ, Hoepelman AI: Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial.[erratum appears in Ann Intern Med. 2005 Nov 1;143(9):695 Note: dosage error in text][summary for patients in Ann Intern Med. 2005 Sep 6;143(5):I38; PMID: 16144888]. Annals of Internal Medicine. 2005, 143 (5): 337-346.CrossRefPubMed
35.
Mulligan K, Yang Y, Wininger DA, Koletar SL, Parker RA, Alston-Smith BL, Schouten JT, Fielding RA, Basar MT, Grinspoon S: Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007, 21 (1): 47-57. 10.1097/QAD.0b013e328011220e.CrossRefPubMed
36.
Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, et al: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.[see comment]. Lancet. 2004, 363 (9407): 429-438. 10.1016/S0140-6736(04)15489-5.CrossRefPubMed
37.
Cavalcanti RB, Raboud J, Shen S, Kain KC, Cheung A, Walmsley S: A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.[see comment]. Journal of Infectious Diseases. 2007, 195 (12): 1754-1761. 10.1086/518005.CrossRefPubMed
38.
Coll B, van Wijk JPH, Parra S, Castro Cabezas M, Hoepelman IM, Alonso-Villaverde C, de Koning EJP, Camps J, Ferre N, Rabelink TJ, et al: Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. European Journal of Pharmacology. 2006, 544 (1-3): 104-110. 10.1016/j.ejphar.2006.06.014.CrossRefPubMed
39.
Gavrila A, Hsu W, Tsiodras S, Doweiko J, Gautam S, Martin L, Moses AC, Karchmer AW, Mantzoros CS: Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 × 2 factorial, randomized, double-blinded, placebo-controlled trial. Clinical Infectious Diseases. 2005, 40 (5): 745-749. 10.1086/427697.CrossRefPubMed
40.
Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S: Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. JAMA. 2000, 284 (4): 472-477. 10.1001/jama.284.4.472.CrossRefPubMed
41.
Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial.[see comment]. Annals of Internal Medicine. 2004, 140 (10): 786-794.CrossRefPubMed
42.
Haider DG, Schindler K, Mittermayer F, Muller M, Nowotny P, Rieger A, Luger A, Ludvik B, Wolzt M: Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.[erratum appears in Clin Pharmacol Ther. 2007 Apr;81(4):611]. Clinical Pharmacology & Therapeutics. 2007, 81 (4): 580-585.CrossRef
43.
Kohli R, Shevitz A, Gorbach S, Wanke C: A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy. HIV Medicine. 2007, 8 (7): 420-426. 10.1111/j.1468-1293.2007.00488.x.CrossRefPubMed
44.
Kovacic JC, Martin A, Carey D, Wand H, Mallon PWG, Feneley MP, Emery S, Cooper DA, Carr A, Investigators R: Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy. Antiviral Therapy. 2005, 10 (1): 135-143.PubMed
45.
Martinez E, Domingo P, Ribera E, Milinkovic A, Arroyo JA, Conget I, Perez-Cuevas JB, Casamitjana R, de Lazzari E, Bianchi L, et al: Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antiviral Therapy. 2003, 8 (5): 403-410.PubMed
46.
Saint-Marc T, Touraine JL: Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999, 13 (8): 1000-1002. 10.1097/00002030-199905280-00023.CrossRefPubMed
47.
Silic A, Janez A, Tomazic J, Karner P, Vidmar L, Sharma P, Maticic M: Effect of rosiglitazone and metformin on insulin resistance in patients infected with human immunodeficiency virus receiving highly active antiretroviral therapy containing protease inhibitor: randomized prospective controlled clinical trial. Croatian Medical Journal. 2007, 48 (6): 791-799. 10.3325/cmj.2007.6.791.CrossRefPubMedPubMedCentral
48.
Sutinen J, Hakkinen A-M, Westerbacka J, Seppala-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, Yki-Jarvinen H: Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Antiviral Therapy. 2003, 8 (3): 199-207.PubMed
49.
Tomazic J, Karner P, Vidmar L, Maticic M, Sharma PM, Janez A: Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART. Acta Dermatovenerologica Alpina, Panonica et Adriatica. 2005, 14 (3): 99-105.
50.
Yki-Jarvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P, Hamsten A: Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arteriosclerosis, Thrombosis & Vascular Biology. 2003, 23 (4): 688-694.CrossRef
51.
Slama L, Lanoy E, Valantin M-A, Bastard J-P, Chermak A, Boutekatjirt A, William-Faltaos D, Billaud E, Molina J-M, Capeau J, et al: Effect of pioglitazone on HIV-1-related lipodystrophy: a randomized double-blind placebo-controlled trial (ANRS 113). Antiviral Therapy. 2008, 13 (1): 67-76.PubMed
52.
Blumer R, van der Valk M, Achermans M, Endert E, Serlie M, Reiss P, Sauerwein H: A rosiglitazone-induced increase in adiponectin does not improve glucose metabolism in HIV-infected patients with overt lipoatrophy. Am J Physiol Endocrinol Metab. 2009, 297: E1097-E1104. 10.1152/ajpendo.90988.2008.CrossRefPubMed
53.
Schindler K, Rieger A, Tura A, Gmeinhardt B, Touzeau-Romer V, Haider D, Pacini G, Ludvik B, Schindler K, Rieger A, et al: The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART). Hormone & Metabolic Research. 2009, 41 (7): 573-579.CrossRef
54.
Mantzoros C, Brennan A: Combination of Insulin Sensitizer and Leptin as Treatment for HAART-Inducted Metabolic Syndrome. 2008, Boston: Beth Isreal Deaconess Medical Center, ClinicalTrials.gov identifier: NCT00362440
55.
Lassa-Claxton S, Cade T, Yarasheski K: Myocardial Function and FFA Metabolism in HIV Metabolic Syndrome. 2010, St. Louis: Washington University School of Medicine, ClinicalTrials.gov identifier: NCT00656851
56.
Lassa-Claxton S, Laciny E, Yarasheski K: Exercise and Pioglitazone for HIV-Metabolic Syndromes. 2009, St. Louis: National Institute of Diabetes and Digestions, ClinicalTrials.gov identifier: NCT00639457
57.
Galli M, Ridolfo AL, Adorni F, Cappelletti A, Morelli P, Massetto B, Piazza M, Gianelli E, Vaccarezza M, Gervasoni C, et al: Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antiviral Therapy. 2003, 8 (4): 347-354.PubMed
58.
Hadigan C, Rabe J, Grinspoon S: Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients with fat redistribution and insulin resistance. Journal of Clinical Endocrinology & Metabolism. 2002, 87 (10): 4611-4615.CrossRef
59.
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B: Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009, 32 (1): 193-203. 10.2337/dc08-9025.CrossRefPubMedPubMedCentral
60.
Salpeter SR, Buckley NS, Kahn JA, Salpeter EE, Salpeter SR, Buckley NS, Kahn JA, Salpeter EE: Meta-analysis: metformin treatment in persons at risk for diabetes mellitus.[see comment]. American Journal of Medicine. 2008, 121 (2): 149-157. 10.1016/j.amjmed.2007.09.016. e142CrossRefPubMed
Metadata
Title
The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials
Authors
Siddharth H Sheth
Robin J Larson
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2010
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-10-183

Other articles of this Issue 1/2010

BMC Infectious Diseases 1/2010 Go to the issue

Research article

Hospitalized adult patients with 2009 influenza A(H1N1) in Beijing, China: risk factors for hospital mortality

Research article

High prevalence of fecal carriage of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric unit in Madagascar

Research article

Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: Clinical and microbiological characteristics in Taiwan, 2001-2008

Research article

Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007

Case report

Corynebacterium mucifaciensin an immunocompetent patient with cavitary pneumonia

Research article

Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits